Pfizer stock slipped about 0.7% to $25.19 after The Wall Street Journal reported on an inquiry looking into the suggestion ...

Federal prosecutors in Manhattan are probing a claim by GSK that Pfizer delayed announcing its COVID shot's success in 2020 ...

The inquiry is looking into a politically explosive suggestion that Pfizer delayed announcing a successful vaccine against ...

President Trump has claimed in the past Pfizer sat on positive vaccine data, but no evidence has supported the accusation.

Pfizer (PFE) and other COVID shot makers such as Moderna (MRNA) will face investor scrutiny as FDA's top vaccine regulator Dr ...

Pfizer's $25 support holds strong, with institutional buying signals and growth potential in oncology. Click here to read an ...

Healthcare stocks have been out of vogue with investors since late 2022. Myriad reasons underlie the negative sentiment ...

Trump has claimed the company delayed an announcement for its vaccine until after the 2020 presidential election.

Pfizer shares are trading lower Wednesday after a Wall Street Journal report revealed that U.S. prosecutors are investigating ...

Pfizer's stock has recently struggled but remains a bargain with generous dividends. Is now a good time to invest in PFE?

The ongoing investigation by Wyden and his Democratic compatriots from the Finance Committee has pointed the finger at ...

With the market underpricing its earnings stability and future catalysts, Pfizer presents a compelling defensive investment ...